Literature DB >> 24246207

Registry of people with diabetes in three Latin American countries: a suitable approach to evaluate the quality of health care provided to people with type 2 diabetes.

V Commendatore1, G Dieuzeide, C Faingold, G Fuente, D Luján, P Aschner, S Lapertosa, J Villena Chávez, J Elgart, J J Gagliardino.   

Abstract

AIMS: To implement a patient registry and collect data related to the care provided to people with type 2 diabetes in six specialized centers of three Latin American countries, measure the quality of such care using a standardized form (QUALIDIAB) that collects information on different quality of care indicators, and analyze the potential of collecting this information for improving quality of care and conducting clinical research.
METHODS: We collected data on clinical, metabolic and therapeutic indicators, micro- and macrovascular complications, rate of use of diagnostic and therapeutic elements and hospitalization of patients with type 2 diabetes in six diabetes centers, four in Argentina and one each in Colombia and Peru.
RESULTS: We analyzed 1157 records from patients with type 2 diabetes (Argentina, 668; Colombia, 220; Peru, 269); 39 records were discarded because of data entry errors or inconsistencies. The data demonstrated frequency performance deficiencies in several procedures, including foot and ocular fundus examination and various cardiovascular screening tests. In contrast, HbA1c and cardiovascular risk factor assessments were performed with a greater frequency than recommended by international guidelines. Management of insulin therapy was sub-optimal, and deficiencies were also noted among diabetes education indicators.
CONCLUSIONS: Patient registry was successfully implemented in these clinics following an interactive educational program. The data obtained provide useful information as to deficiencies in care and may be used to guide quality of care improvement efforts.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 24246207     DOI: 10.1111/ijcp.12208

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  6 in total

1.  The burden of diabetes in Argentina.

Authors:  Lorena Gonzalez; Joaquin E Caporale; Jorge F Elgart; Juan J Gagliardino
Journal:  Glob J Health Sci       Date:  2014-11-17

2.  Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America.

Authors:  Jorge Federico Elgart; Mariana Prestes; Lorena Gonzalez; Enzo Rucci; Juan Jose Gagliardino
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

3.  The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers.

Authors:  Alberto Barcelo; Armando Arredondo; Amparo Gordillo-Tobar; Johanna Segovia; Anthony Qiang
Journal:  J Glob Health       Date:  2017-12       Impact factor: 4.413

4.  Dyslipidemia: The untreated metabolic dysfunction in people with type 2 diabetes in Latin America. ARETAEUS study outcomes.

Authors:  Juan José Gagliardino; Rosario Arechavaleta; Freddy Goldberg Eliaschewitz; Kristy Iglay; Kimberly Brodovicz; Claudio D Gonzalez; Shengsheng Yu; R Ravi Shankar; Olaf Heisel; Paul Keown; Kaan Tunceli
Journal:  J Clin Transl Endocrinol       Date:  2019-01-25

Review 5.  Current State of Diabetes Mellitus Prevalence, Awareness, Treatment, and Control in Latin America: Challenges and Innovative Solutions to Improve Health Outcomes Across the Continent.

Authors:  M Larissa Avilés-Santa; Alberto Monroig-Rivera; Alvin Soto-Soto; Nangel M Lindberg
Journal:  Curr Diab Rep       Date:  2020-10-10       Impact factor: 4.810

6.  Challenges associated with insulin therapy progression among patients with type 2 diabetes: Latin American MOSAIc study baseline data.

Authors:  Bruno Linetzky; Brad Curtis; Gustavo Frechtel; Renan Montenegro; Miguel Escalante Pulido; Oded Stempa; Janaina Martins de Lana; Juan José Gagliardino
Journal:  Diabetol Metab Syndr       Date:  2016-07-22       Impact factor: 3.320

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.